#雅诗兰黛 EL业绩下调股价大跌
Estée Lauder (ticker: EL) said on Wednesday it now anticipates fiscal 2024 sales to range between a 2% decline and a 1% increase from the prior year. In the company's fourth-quarter financial report in August, Estée Lauder said it estimated that sales would increase between 5% and 7% from the prior year.
The company's adjusted earnings per share outlook also was cut to between $2.17 and $2.42 a share from between $3.50 and $3.75 a share.
"While we had a better-than-expected first quarter, we are lowering our fiscal 2024 outlook given incremental external headwinds, namely from the slower growth in overall prestige beauty in Asia travel retail and in mainland China," Chief Executive Fabrizio Freda said in the earnings release. Freda added that the ongoing war in the Middle East also was a risk to the business.
—————
雅诗兰黛在中国的销售也放缓了[doge][doge][挖鼻][挖鼻]
-
Estée Lauder (ticker: EL) said on Wednesday it now anticipates fiscal 2024 sales to range between a 2% decline and a 1% increase from the prior year. In the company's fourth-quarter financial report in August, Estée Lauder said it estimated that sales would increase between 5% and 7% from the prior year.
The company's adjusted earnings per share outlook also was cut to between $2.17 and $2.42 a share from between $3.50 and $3.75 a share.
"While we had a better-than-expected first quarter, we are lowering our fiscal 2024 outlook given incremental external headwinds, namely from the slower growth in overall prestige beauty in Asia travel retail and in mainland China," Chief Executive Fabrizio Freda said in the earnings release. Freda added that the ongoing war in the Middle East also was a risk to the business.
—————
雅诗兰黛在中国的销售也放缓了[doge][doge][挖鼻][挖鼻]
-
*
On this day in 1918, Egon Schiele died from the Spanish flue pandemic. Three days prior, his wife Edith died from the same disease, six months pregnant. The second image is from Egon’s deathbed.
Egon Schiele, Austria(1890-1918)
Self-Portrait with Peacock Waistcoat, Standing (1911)
1918年的这一天,Egon Schiele死于西班牙流行病。 三天前,他的妻子伊迪丝死于同样的疾病,怀孕六个月，第二张图片来自伊贡的临终病床。
On this day in 1918, Egon Schiele died from the Spanish flue pandemic. Three days prior, his wife Edith died from the same disease, six months pregnant. The second image is from Egon’s deathbed.
Egon Schiele, Austria(1890-1918)
Self-Portrait with Peacock Waistcoat, Standing (1911)
1918年的这一天,Egon Schiele死于西班牙流行病。 三天前,他的妻子伊迪丝死于同样的疾病,怀孕六个月，第二张图片来自伊贡的临终病床。
【美国FDA新药快讯】
美国FDA首次批准治疗鼻咽癌药物Loqtorzi(toripalimab-tpzi)
美国FDA于2023年10月27日（星期五）批准Coherus生物科学公司(Coherus BioSciences, Inc.)的toripalimab-tpzi(商品名LOQTORZ)与化疗药物
顺铂(cisplatin)和吉西他滨(gemcitabine)联合用药用于转移性或复发性局部晚期鼻咽癌(nasopharyngeal carcinoma,NPC)的一线治疗。FDA同时还批准toripalimab-tpzi(LOQTORZ)单独用药用于成人治疗复发性不可切除或者转移性鼻咽癌（适用于病程进展中或者接受含铂化疗后的患者）。
Loqtorzi(toripalimab-tpzi)是FDA批准的首个用于治疗鼻咽癌的药物。
On Friday（2023.10.27）, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC). The FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. View full prescribing information for LOQTORZI.
“Today's approval of Loqtorzi is the first approval in the United States of a drug to treat nasopharyngeal carcinoma. When combined with chemotherapy this drug has demonstrated an improvement in overall survival as well as delaying the progression of disease in patients with metastatic or recurrent, locally advanced disease who had not received prior chemotherapy,” stated Richard Pazdur.
详见：https://t.cn/A6WaSNt6
美国FDA首次批准治疗鼻咽癌药物Loqtorzi(toripalimab-tpzi)
美国FDA于2023年10月27日（星期五）批准Coherus生物科学公司(Coherus BioSciences, Inc.)的toripalimab-tpzi(商品名LOQTORZ)与化疗药物
顺铂(cisplatin)和吉西他滨(gemcitabine)联合用药用于转移性或复发性局部晚期鼻咽癌(nasopharyngeal carcinoma,NPC)的一线治疗。FDA同时还批准toripalimab-tpzi(LOQTORZ)单独用药用于成人治疗复发性不可切除或者转移性鼻咽癌（适用于病程进展中或者接受含铂化疗后的患者）。
Loqtorzi(toripalimab-tpzi)是FDA批准的首个用于治疗鼻咽癌的药物。
On Friday（2023.10.27）, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC). The FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. View full prescribing information for LOQTORZI.
“Today's approval of Loqtorzi is the first approval in the United States of a drug to treat nasopharyngeal carcinoma. When combined with chemotherapy this drug has demonstrated an improvement in overall survival as well as delaying the progression of disease in patients with metastatic or recurrent, locally advanced disease who had not received prior chemotherapy,” stated Richard Pazdur.
详见：https://t.cn/A6WaSNt6
✋热门推荐